- Home
- ESGR vs BBIO Comparison
ESGR vs BBIO Comparison
Compare ESGR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGR
- BBIO
- Stock Information
- Founded
- ESGR 2001
- BBIO 2015
- Country
- ESGR Bermuda
- BBIO United States
- Employees
- ESGR N/A
- BBIO N/A
- Industry
- ESGR Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ESGR Finance
- BBIO Health Care
- Exchange
- ESGR Nasdaq
- BBIO Nasdaq
- Market Cap
- ESGR 4.7B
- BBIO 5.6B
- IPO Year
- ESGR N/A
- BBIO 2019
- Fundamental
- Price
- ESGR $332.00
- BBIO $36.85
- Analyst Decision
- ESGR
- BBIO Strong Buy
- Analyst Count
- ESGR 0
- BBIO 12
- Target Price
- ESGR N/A
- BBIO $52.27
- AVG Volume (30 Days)
- ESGR 93.0K
- BBIO 2.8M
- Earning Date
- ESGR 03-04-2025
- BBIO 02-20-2025
- Dividend Yield
- ESGR N/A
- BBIO N/A
- EPS Growth
- ESGR 51.73
- BBIO N/A
- EPS
- ESGR 66.06
- BBIO N/A
- Revenue
- ESGR $1,067,000,000.00
- BBIO $221,902,000.00
- Revenue This Year
- ESGR N/A
- BBIO $2,306.75
- Revenue Next Year
- ESGR N/A
- BBIO N/A
- P/E Ratio
- ESGR $5.03
- BBIO N/A
- Revenue Growth
- ESGR 17.90
- BBIO 2285.27
- 52 Week Low
- ESGR $275.02
- BBIO $21.62
- 52 Week High
- ESGR $348.48
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- ESGR 74.06
- BBIO 63.77
- Support Level
- ESGR $331.22
- BBIO $35.36
- Resistance Level
- ESGR $333.36
- BBIO $39.47
- Average True Range (ATR)
- ESGR 1.29
- BBIO 1.93
- MACD
- ESGR 0.37
- BBIO 0.26
- Stochastic Oscillator
- ESGR 80.03
- BBIO 70.79
About ESGR Enstar Group Limited
Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.